What is Albireo Pharma Cyclically Adjusted Revenue per Share?
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.
Albireo Pharma's adjusted revenue per share for the three months ended in Sep. 2022 was $0.500. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.00 for the trailing ten years ended in Sep. 2022.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.
As of today (2024-04-28), Albireo Pharma's current stock price is $44.15. Albireo Pharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2022 was $0.00. Albireo Pharma's Cyclically Adjusted PS Ratio of today is .
Albireo Pharma Cyclically Adjusted Revenue per Share Historical Data
The historical data trend for Albireo Pharma's Cyclically Adjusted Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Albireo Pharma Cyclically Adjusted Revenue per Share Chart
|
Albireo Pharma Annual Data
|
|
Trend |
Sep12 |
Sep13 |
Sep14 |
Sep15 |
Sep16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
| Cyclically Adjusted Revenue per Share |
|
Get a 7-Day Free Trial
|
|
|
- |
- |
- |
- |
- |
|
Albireo Pharma Quarterly Data
|
|
Dec17 |
Mar18 |
Jun18 |
Sep18 |
Dec18 |
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
| Cyclically Adjusted Revenue per Share |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
- |
- |
- |
- |
- |
Competitive Comparison of Albireo Pharma's Cyclically Adjusted Revenue per Share
For the Biotechnology subindustry, Albireo Pharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Albireo Pharma's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Albireo Pharma's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Albireo Pharma's Cyclically Adjusted PS Ratio falls into.
Albireo Pharma Cyclically Adjusted Revenue per Share Calculation
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.
What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?
Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.
If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.
We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
For example, Albireo Pharma's adjusted Revenue per Share data for the three months ended in Sep. 2022 was:
| Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Sep. 2022 (Change) | * | Current CPI (Sep. 2022) |
| = | 0.5 | / | 125.2265 | * | 125.2265 |
| = | 0.500 |
Current CPI (Sep. 2022) = 125.2265.
Albireo Pharma Quarterly Data
|
Revenue per Share |
CPI |
Adj_RevenuePerShare |
| 201212 |
0.000 |
96.871 |
0.000 |
| 201303 |
0.000 |
98.209 |
0.000 |
| 201306 |
0.000 |
98.518 |
0.000 |
| 201309 |
0.000 |
98.790 |
0.000 |
| 201312 |
0.000 |
98.326 |
0.000 |
| 201403 |
0.000 |
99.695 |
0.000 |
| 201406 |
0.000 |
100.560 |
0.000 |
| 201409 |
0.000 |
100.428 |
0.000 |
| 201412 |
0.000 |
99.070 |
0.000 |
| 201503 |
0.000 |
99.621 |
0.000 |
| 201506 |
0.000 |
100.684 |
0.000 |
| 201509 |
0.000 |
100.392 |
0.000 |
| 201512 |
0.000 |
99.792 |
0.000 |
| 201603 |
0.000 |
100.470 |
0.000 |
| 201606 |
0.000 |
101.688 |
0.000 |
| 201609 |
0.000 |
101.861 |
0.000 |
| 201612 |
0.000 |
101.863 |
0.000 |
| 201703 |
0.000 |
102.862 |
0.000 |
| 201706 |
0.000 |
103.349 |
0.000 |
| 201709 |
0.000 |
104.136 |
0.000 |
| 201712 |
0.000 |
104.011 |
0.000 |
| 201803 |
1.028 |
105.290 |
1.223 |
| 201806 |
0.061 |
106.317 |
0.072 |
| 201809 |
0.020 |
106.507 |
0.024 |
| 201812 |
0.048 |
105.998 |
0.057 |
| 201903 |
0.047 |
107.251 |
0.055 |
| 201906 |
0.101 |
108.070 |
0.117 |
| 201909 |
0.109 |
108.329 |
0.126 |
| 201912 |
0.506 |
108.420 |
0.584 |
| 202003 |
0.110 |
108.902 |
0.126 |
| 202006 |
0.128 |
108.767 |
0.147 |
| 202009 |
0.136 |
109.815 |
0.155 |
| 202012 |
0.142 |
109.897 |
0.162 |
| 202103 |
0.103 |
111.754 |
0.115 |
| 202106 |
0.126 |
114.631 |
0.138 |
| 202109 |
0.186 |
115.734 |
0.201 |
| 202112 |
1.686 |
117.630 |
1.795 |
| 202203 |
0.353 |
121.301 |
0.364 |
| 202206 |
0.419 |
125.017 |
0.420 |
| 202209 |
0.500 |
125.227 |
0.500 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
Albireo Pharma (Albireo Pharma) Business Description
Traded in Other Exchanges
N/A
Address
53 State Street, 19th Floor, Boston, MA, USA, 02109
Albireo Pharma Inc is a commercial-stage biopharmaceutical company. It focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. The Company's product pipeline includes Bylvay, which is approved in the United States and Europe; elobixibat, which is approved in Japan for the treatment of chronic constipation; A3907, its Phase 1 lead candidate for the treatment of adult liver diseases; and A2342, it's a lead preclinical candidate for the treatment of adult viral and liver diseases.
Executives
| Harford Simon N.r. |
officer: CFO and Treasurer |
AVON PRODUCTS, INC., 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105 |
| Pamela Stephenson |
officer: Chief Commercial Officer |
C/O ZYNERBA PHARMACEUTICALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333 |
| Martha J. Carter |
officer: Chief Regulatory Officer |
C/O AEGERION PHARMACEUTICALS, INC., 89 HEADQUARTERS PLAZA, SUITE 1212, MORRISTOWN NJ 07960 |
| Jan Mattsson |
officer: Chief Operating Officer |
C/O ALBIREO PHARMA, INC., 50 MILK STREET, 16TH FLOOR, BOSTON MA 02109 |
| Cooper Ronald Harold Wilfred |
director, officer: President and CEO |
C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140 |
| Michelle Graham |
officer: Chief Human Resources Officer |
10000 WEHRLE DRIVE, CLARENCE NY 14031 |
| Jason Duncan |
officer: General Counsel |
C/O ALBIREO PHARMA, INC., 10 POST OFFICE SQUARE, SUITE 502 SOUTH, BOSTON MA 02109 |
| Paul Streck |
officer: Chief Medical Officer |
10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807 |
| Craig C. Hopkinson |
director |
852 WINTER STREET, WALTHAM MA 02451 |
| Perceptive Life Sciences Master Fund Ltd |
10 percent owner |
C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
| Susan Alesina |
director |
C/O ALBIREO PHARMA, INC., 53 STATE STREET, 19TH FLOOR, BOSTON MA 02109 |
| Habib J Dable |
director |
C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139 |
| Patrick Taylor Horn |
officer: Chief Medical Officer |
C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472 |
| Perceptive Advisors Llc |
10 percent owner |
51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
| Joseph Edelman |
10 percent owner |
C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Albireo Pharma (Albireo Pharma) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALBO has been successfully added to your